Stiefel Trades On Break

Stiefel Laboratories' term loan broke last Wednesday around 100 1/2-101, tightened a bit during the day and was trading around 100 3/4-101 by day's end.

  • 12 Jan 2007
Email a colleague
Request a PDF

Stiefel Laboratories' term loan broke last Wednesday around 100 1/2-101, tightened a bit during the day and was trading around 100 3/4-101 by day's end. About $50 to $75 million traded. "It was reasonably active," one dealer said.

Two weeks ago Deutsche Bank, which leads the credit, flexed pricing down 25 basis points on the first lien (CIN, 1/8). The deal consists of a $623 million first-lien term loan priced at LIBOR plus 2 1/4% and a $75 million revolver priced at LIBOR plus 2 1/2%. There is also a $150 million second-lien term loan priced at LIBOR plus 5% with call protection of 102, 101.

The deal backs the acquisition of Palo Alto, Calif.-based Connetics Corp., which was completed Dec. 28. Coral Gables, Fla.-based Stiefel is a pharmaceutical company specializing in dermatology; brands include Sarna and Duac. Connetics was a publicly held pharmaceutical company also focused on developments for the dermatology market. A Stiefel spokeswoman declined comment.

  • 12 Jan 2007

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Share % by Volume
1 Societe Generale 15.35
2 Rabobank 14.41
3 Morgan Stanley 11.73
4 Barclays 8.99
5 Credit Agricole 7.57

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • 27 Feb 2017
1 Wells Fargo Securities 11,897.40 33 11.83%
2 Bank of America Merrill Lynch 9,837.56 29 9.78%
3 Citi 9,714.54 32 9.66%
4 JPMorgan 7,997.38 24 7.95%
5 Credit Suisse 6,335.67 14 6.30%